These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8402109)
1. Systemic leakage during isolated limb perfusion for melanoma. Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR Br J Surg; 1993 Sep; 80(9):1124-6. PubMed ID: 8402109 [TBL] [Abstract][Full Text] [Related]
2. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187 [TBL] [Abstract][Full Text] [Related]
3. Continuous leakage measurement during hyperthermic isolated limb perfusion. Daryanani D; Komdeur R; Ter Veen J; Nijhuis PH; Piers DA; Hoekstra HJ Ann Surg Oncol; 2001 Aug; 8(7):566-72. PubMed ID: 11508617 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb. Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997 [TBL] [Abstract][Full Text] [Related]
5. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699 [TBL] [Abstract][Full Text] [Related]
6. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Sonneveld EJ; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; van Dongen JA; Kroon BB Eur J Surg Oncol; 1996 Oct; 22(5):521-7. PubMed ID: 8903497 [TBL] [Abstract][Full Text] [Related]
7. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma]. Kettelhack C; Hohenberger P; Schlag PM Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487 [TBL] [Abstract][Full Text] [Related]
8. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Minor DR; Allen RE; Alberts D; Peng YM; Tardelli G; Hutchinson J Cancer; 1985 Jun; 55(11):2638-44. PubMed ID: 3995475 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; Hart AA Surgery; 1994 Jan; 115(1):39-45. PubMed ID: 8284759 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy by regional perfusion for limb melanoma. Krementz ET; Carter RD; Sutherland CM; Muchmore JH Am Surg; 1987 Mar; 53(3):133-40. PubMed ID: 3103506 [TBL] [Abstract][Full Text] [Related]
11. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Vrouenraets BC; Eggermont AM; Klaase JM; Van Geel BN; Van Dongen JA; Kroon BB Eur J Surg Oncol; 1994 Dec; 20(6):681-5. PubMed ID: 7995421 [TBL] [Abstract][Full Text] [Related]
12. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854 [TBL] [Abstract][Full Text] [Related]
13. Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma. Würl P; Eichfeld U; Pauer HD; Gläser A; Rose U; Dralle H Surg Today; 1997; 27(8):719-25. PubMed ID: 9306586 [TBL] [Abstract][Full Text] [Related]
14. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030 [TBL] [Abstract][Full Text] [Related]
15. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Kroon BB; Van Geel AN; Benckhuijsen C; Wieberdink J Anticancer Res; 1987; 7(3 Pt B):441-2. PubMed ID: 3631900 [TBL] [Abstract][Full Text] [Related]
16. Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity. Paulsen IF; Chakera AH; Schmidt G; Drejøe J; Klyver H; Oturai PS; Hesse B; Drzewiecki K; Mortensen J Clin Physiol Funct Imaging; 2015 Jul; 35(4):301-5. PubMed ID: 24902761 [TBL] [Abstract][Full Text] [Related]
17. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986 [TBL] [Abstract][Full Text] [Related]
18. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726 [TBL] [Abstract][Full Text] [Related]
19. Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. Wu Z; Roberts MS; Parsons PG; Smithers BM Melanoma Res; 1997 Feb; 7(1):19-26. PubMed ID: 9067961 [TBL] [Abstract][Full Text] [Related]
20. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma. Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]